脑内纤维溶解疗法:过去,现在和未来
Peter K Moore1, Daniel M Hershberger2, Christopher D Barrett3
1Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Chest
|September 12, 2025
概括
对于复杂的肺部喷液/肺血栓炎的脑内纤维溶解药物治疗是无效的,导致长时间住院和高成本. 了解耐药机制可以改善治疗结果,减少医疗保健支出.
科学领域:
- 肺部医学 肺部医学
- 心血管医学 心血管医学
- 生物化学 生物化学
背景情况:
- 纤维解和共享一个历史的联系,与早期的塑原激活剂发现从Streptococcus物种.
- 塑原激活剂的第一个临床用途是用于肺部输液的腹腔内链激酶.
- 目前的疗法使用复合组织等离子体激活剂和脱氧核糖核酶-1,但仍然低效.
研究的目的:
- 为了提供一个关于脑内膜纤维溶解的历史概述.
- 审查当前临床纤维溶解药物治疗复杂的肺/肺.
- 突出在抗抗内纤维解药疗法的病理生物学方面的知识差距.
主要方法:
- 历史文献评论. 历史文献评论.
- 分析纤维溶解疗法当前的临床实践.
- 识别腔空间纤维解的研究缺口.
主要成果:
- 目前的腹腔内纤维解药疗法与平均14天的住院时间有关.
- 许多患者经历了残留的多流,需要手术.
- 大量的医疗保健支出与这些治疗有关.
结论:
- 更好地了解腔空间纤维解酶机制可以提高预后.
- 知识的进步可能会指导精密疗法,以获得更好的患者结果.
- 解决对内纤维溶解药物治疗的耐药性可以降低医疗保健成本.
相关概念视频
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
329
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
329
Pulmonary Embolism III: Nursing Management
369
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
369
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Flail Chest-II
543
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
543
Clot Retraction and Fibrinolysis
8.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
466
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
466


